Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab + EPOCH in Refractory/Relapsed CD20+ NHL
NCT00006669Phase 2Withdrawn
- Sponsor
- MedStar Health Research Institute
- Start
- Sep 1999
- Primary completion
- Jan 2000
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in non-Hodgkin lymphoma (NHL), sponsored by MedStar Health Research Institute. Planned start Sep 1999; status: withdrawn.
02
Drugs
rituximab
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00006669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006669.